Anales de la RANM

205 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 INFECCIÓN POR HANTAVIRUS Bouza E, et al. An RANM. 2026;143(01): 182 - 206 233. Geladari V, Sarafidis PA, Alexandrou ME, Fai- tatzidou D, Nikolaidou C, Stangou M, et al. A patient with dialysis-dependent acute kid- ney injury due to hantavirus complicated with SARS-CoV-2 infection. Clin Nephrol Case Stud. 2022;10:64-70. 234. Rista E, Pilaca A, Akshija I, Rama A, Harja E, Puca E, et al. Hemorrhagic fever with renal syn- drome in Albania. Focus on predictors of acute kidney injury in HFRS. J Clin Virol. 2017;91:25- 30. 235. Vaheri A, Henttonen H, Voutilainen L, Mustonen J, Sironen T, Vapalahti O. Hantavirus infections in Europe and their impact on public health. Rev Med Virol. 2013;23(1):35-49. 236. Kim S, Sung SH, An HR, Jun YH, Yu M, Ryu DR, et al. A case report of crescentic glomerulone- phritis associated with Hantaan virus infection. Nephrol Dial Transplant. 2010;25(8):2790-2. 237. Novo R, Gagnadoux MF, Le Guenno Y, Gubler MC, Niaudet P, Guyot C, et al. Chronic renal fai- lure after Puumala virus infection. Pediatr Ne- phrol. 1999;13(9):934-5. 238. van Ypersele de Strihou C, Méry JP. Hantavirus- related acute interstitial nephritis in western Eu- rope. Expansion of a world-wide zoonosis. Q J Med. 1989;73(270):941-50. 239. Martinuč Bergoč M, Lindič J, Kovač D, Ferluga D, Pajek J. Successful treatment of severe han- tavirus nephritis with corticosteroids: a case report and literature review. Ther Apher Dial. 2013;17(4):402-6. 240. Easterbrook JD, Klein SL. Corticosteroids mo- dulate Seoul virus infection, regulatory T-cell responses and matrix metalloprotease 9 expres- sion in male, but not female, Norway rats. J Gen Virol. 2008;89(Pt 11):2723-30. 241. Seitsonen E, Hynninen M, Kolho E, Kallio-Ko- kko H, Pettilä V. Corticosteroids combined with continuous veno-venous hemodiafiltration for treatment of hantavirus pulmonary syndrome caused by Puumala virus infection. Eur J Clin Microbiol Infect Dis. 2006;25(4):261-6. 242. Dunst R, Mettang T, Kuhlmann U. Severe throm- bocytopenia and response to corticosteroids in a case of nephropathia epidemica. Am J Kidney Dis. 1998;31(1):116-20. 243. Kyriakidis I, Papa A. Serum TNF-α, sTNFR1, IL- 6, IL-8 and IL-10 levels in hemorrhagic fever with renal syndrome. Virus Res. 2013;175(1):91-4. 244. Taylor SL, Krempel RL, Schmaljohn CS. Inhibi- tion of TNF-alpha-induced activation of NF-ka- ppaB by hantavirus nucleocapsid proteins. Ann N Y Acad Sci. 2009;1171 Suppl 1:E86-93. 245. Strandin T, Hepojoki J, Wang H, Vaheri A, Lan- kinen H. Hantaviruses and TNF-alpha act syner- gistically to induce ERK1/2 inactivation in Vero E6 cells. Virol J. 2008;5:110. 246. Linderholm M, Ahlm C, Settergren B, Waage A, Tärnvik A. Elevated plasma levels of tumor necrosis factor (TNF)-alpha, soluble TNF recep- tors, interleukin (IL)-6, and IL-10 in patients with hemorrhagic fever with renal syndrome. J Infect Dis. 1996;173(1):38-43. 247. Alkharsah KR. VEGF Upregulation in Viral In- fections and Its Possible Therapeutic Implica- tions. Int J Mol Sci. 2018;19(6). 248. Wang W, Zhang Y, Li Y, Pan L, Bai L, Zhuang Y, et al. Dysregulation of the β3 integrin-VEGFR2 complex in Hantaan virus-directed hyperper- meability upon treatment with VEGF. Arch Vi- rol. 2012;157(6):1051-61. 249. Gavrilovskaya I, Gorbunova E, Koster F, Mac- kow E. Elevated VEGF Levels in Pulmonary Ede- ma Fluid and PBMCs from Patients with Acute Hantavirus Pulmonary Syndrome. Adv Virol. 2012;2012:674360. 250. Gorbunova EE, Gavrilovskaya IN, Pepini T, Mac- kow ER. VEGFR2 and Src kinase inhibitors sup- press Andes virus-induced endothelial cell per- meability. J Virol. 2011;85(5):2296-303. 251. Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, et al. Prospective, double- blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemo- rrhagic fever with renal syndrome. J Infect Dis. 1991;164(6):1119-27. 252. Moreli ML, Marques-Silva AC, Pimentel VA, da Costa VG. Effectiveness of the ribavirin in treatment of hantavirus infections in the Ame- ricas and Eurasia: a meta-analysis. Virusdisease. 2014;25(3):385-9. 253. Khaiboullina SF, Rizvanov AA, Lombardi VC, Morzunov SP, Reis HJ, Palotás A, et al. Andes-vi- rus-induced cytokine storm is partially suppres- sed by ribavirin. Antivir Ther. 2013;18(4):575- 84. 254. Safronetz D, Haddock E, Feldmann F, Ebihara H, Feldmann H. In vitro and in vivo activity of ri- bavirin against Andes virus infection. PLoS One. 2011;6(8):e23560. 255. Marcus KA, Johann-Liang R, Powers JH. Riba- virin trials and hantavirus--what we should not conclude. Clin Infect Dis. 2005;40(10):1550-1. 256. Mertz GJ, Miedzinski L, Goade D, Pavia AT, Hje- lle B, Hansbarger CO, et al. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis. 2004;39(9):1307-13. 257. Murphy ME, Kariwa H, Mizutani T, Tanabe H, Yoshimatsu K, Arikawa J, et al. Characterization of in vitro and in vivo antiviral activity of lacto- ferrin and ribavirin upon hantavirus. J Vet Med Sci. 2001;63(6):637-45. 258. Chapman LE, Mertz GJ, Peters CJ, Jolson HM, Khan AS, Ksiazek TG, et al. Intravenous ribavi- rin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label ex- perience. Ribavirin Study Group. Antivir Ther. 1999;4(4):211-9. 259. Vial PA, Valdivieso F, Calvo M, Rioseco ML, Ri- quelme R, Araneda A, et al. A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syn- drome caused by Andes virus. Antivir Ther. 2015;20(4):377-86. 260. Hooper JW, Ferro AM, Wahl-Jensen V. Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus. J Virol. 2008;82(3):1332-8. 261. Brocato RL, Wu H, Kwilas SA, Principe LM, Jos- leyn M, Shamblin J, et al. Preclinical evaluation of a fully human, quadrivalent-hantavirus polyclo-